Penn to receive $467M under settlement with BioNTech over Covid-19 vaccine royalties
Penn has reached an agreement to resolve a dispute over Covid-19 royalties the Philadelphia university alleged it was owed.
FiercePharma4d
BioNTech inks settlements with NIH, Penn in COVID-19 vaccine royalty disputes
The German drugmaker will pay the NIH $791.5 million, while the University of Pennsylvania will get up to $467 million ...
Penn’s royalties from Pfizer-BioNTech COVID-19 vaccine grow to at least $2 billion after new settlement
The new $467 million includes $400 million in royalties for the Pfizer-BioNTech vaccine from 2020 through 2023.
Seeking Alpha on MSN11d
BioNTech inks $1B settlements with NIH and Penn to resolve COVID vaccine royalty claims
BioNTech (BNTX) stock slipped after signing $1B deals with NIH and the University of Pennsylvania to resolve COVID vaccine ...
BioNTech enters settlement with US agency, UPenn over COVID vaccine royalties
BioNTech has entered into two separate settlement agreements with the U.S. National Institutes of Health and the University ...
BioNTech to pay $467M in settlement agreement with University of Pennsylvania
In a regulatory filing, BioNTech (BNTX) said, “BioNTech previously disclosed that it was in discussions with the University ...
Seeking Alpha11d
BioNTech inks $1B settlements with NIH and Penn to resolve COVID vaccine royalty claims
Concurrently, BioNTech (BNTX) announced a settlement agreement worth $467M with Penn to resolve a lawsuit filed by the university over royalty claims related to the COVID-19 shot. The deal ...
BioNTech to Pay Up to $1.26 Billion in Covid-19 Vaccine Settlements With NIH, Penn
Pfizer has agreed to reimburse BioNTech for $364.5 million of the claimed royalties paid to NIH and $170.0 million of the claimed royalties paid to the University of Pennsylvania. Write to Dean Seal ...
Nasdaq11d
Pfizer to Reimburse BioNTech for COVID Vaccine Royalty Settlements
The settlements will see BioNTech pay $791.5 million to NIH and $467 million to Penn, with Pfizer (PFE), its vaccine partner, reimbursing part of these payments. The dispute stemmed from claims by ...